Editorial: Percutaneous mitral valvotomy: Balloon made in Japan still dominates the world  by Watanabe, Nozomi
Journal of Cardiology Cases 13 (2016) 169–170Editorial






Contents lists available at ScienceDirect
Journal of Cardiology Cases
jo u rn al ho m epag e: ww w.els evier . c om / lo cat e/ jcc as eBalloon mitral valvotomy (balloon mitral valvuloplasty/percu-
taneous transvenous mitral commissurotomy) has been estab-
lished as an effective procedure for rheumatic mitral stenosis, since
the interventional procedure was ﬁrstly introduced by the
Japanese cardiologist Kanji Inoue MD in the early 1980s
[1,2]. The interventional procedure utilizing the Inoue balloon
has been reported to be technically successful in over 90% of
patients with its excellent long-term durability. In these decades,
the prevalence of rheumatic fever has been decreasing in
developed countries, and the number of patients with rheumatic
mitral stenosis has also been decreasing. Nevertheless, rheumatic
fever still affects numerous areas in the nonindustrialized world,
and mitral valve balloon valvotomy using the Inoue balloon helps
patients worldwide who are suffering with stenotic mitral valve.
The Inoue balloon has been used internationally as the ﬁrst choice
for catheter intervention for signiﬁcant mitral stenosis for over
30 years, with its high technical feasibility and excellent results.
The effectiveness of balloon valvotomy is known to be related to
the etiology of valve stenosis, and severe rheumatic mitral stenosis
with minimally deformed or calciﬁed submitral apparatus was
originally considered as an ideal candidate for the balloon mitral
valvotomy. Patients with severely calciﬁed valves or subvalvular
apparatus are generally considered as candidates for surgical
intervention, and other structural ﬁndings might suggest balloon
valvuloplasty to be less likely successful or even contraindicated.
Transthoracic and transesophageal echocardiography play a
major role in the patient selection for balloon mitral valvotomy.
Etiology and severity of the mitral stenosis should be observed by
echocardiography as a ﬁrst step in considering the indication of
balloon mitral valvotomy. Once the degree is diagnosed as
moderate to severe, its functional disability should be investigated
considering other clinical ﬁndings. Pulmonary pressures at rest
and with exercise are the important parameters in considering the
indication of intervention. Coexistence of more than moderate
mitral regurgitation and the presence of left atrial thrombus are
considered as contraindications to balloon mitral valvotomyDOI of original article: http://dx.doi.org/10.1016/j.jccase.2016.01.011
http://dx.doi.org/10.1016/j.jccase.2016.03.009
1878-5409/ 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All rights[3]. Subvalvular involvement and its degree should also be
carefully evaluated by transthoracic and transesophageal echo-
cardiography. A recent study has reported that balloon valvotomy
is effective even in patients with mild–moderate degree of
calciﬁcation [4]. According to their results, long-term functional
outcome depends on calciﬁcation extent, patient characteristics,
and immediate results of valvuloplasty. The authors suggested that
percutaneous mitral balloon valvotomy can be considered as ﬁrst-
line treatment in selected patients with calciﬁc mitral stenosis.
Echocardiography also plays an important role during the
catheter intervention. Echocardiographic guidance is necessary in
the stepwise dilation technique using the Inoue balloon, which
comes in four sizes, ranging from 24 to 30 mm. The balloon size is
chosen depending on the body size of the patients, and the ﬁrst
inﬂation is performed to the minimum diameter of the balloon
chosen. After the initial ballooning, morphological changes in the
mitral valve should be observed, according to the types of valve
split. Mitral valve area can be measured by 2D or 3D planimetry
with transthoracic short-axis view. Mitral valve area should be
measured in its smallest plane, which should be carefully scanned
with 2D echocardiography. Real-time 3D scanning helps in
imaging the smallest area of the stenotic valve oriﬁce during
balloon valvuloplasty [5]. Echocardiographic ﬁndings immediately
after valvuloplasty are the key to determine when to stop the
procedure. Mitral valve area, pattern of crackle, existence and
degree of regurgitation should be carefully observed after each
ballooning procedure. Pre/post-procedural echocardiography also
contributes to ﬁnd other abnormal ﬁndings. A manuscript from
India in the current issue of Journal of Cardiology Cases [6] reports
an incidental diagnosis of subclinical patent ductus arteriosus by
preoperative transthoracic echocardiography before balloon val-
votomy for severe mitral stenosis. Once other cardiac disease was
found, clinical signiﬁcance and hemodynamic impact of the
abnormal ﬁnding in combination with mitral stenosis should be
carefully investigated. Iatrogenic atrial septal defect caused by
atrial septal puncture during the procedure can be imaged by using
color Doppler echocardiography. Serial follow-up study by
transesophageal echocardiography has shown that there was a
signiﬁcant decrease in the diameter of an interatrial septal defect reserved.
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shunt remained in 20% of the study subject 6 months after
valvotomy [7].
Balloon mitral valvotomy is feasible in patients with recurrent
mitral stenosis who have undergone surgical commissurotomy.
Overall results are good, although they are slightly less satisfactory
when compared with those of primary balloon commissurotomy. A
case of successful percutaneous balloon mitral valvotomy for
bioprosthetic stenosis is also reported by the group of the balloon
pioneer. Usefulness of catheter commissurotomy for those
different conditions should be evaluated.
Successful results of percutaneous balloon valvotomy in
patients with nonrheumatic mitral stenosis have been reported.
Lo et al. reported 7 symptomatic patients with stenotic double-
oriﬁce mitral valve of incomplete bridge type. They performed
stepwise dilations only to the posteromedial oriﬁce with the use of
an Inoue balloon, which resulted in successful split of the ﬁbrous
bridge tissue between the leaﬂets [8]. Nonrheumatic calciﬁc/
degenerative change in the mitral valve has been recently reported
as an important cause of clinically signiﬁcant mitral stenosis in this
aging society [9]. A case of successful balloon valvotomy in a
patient with nonrheumatic calciﬁc mitral stenosis has been
reported [10], and further clinical evaluation should be needed
to appreciate the feasibility, safety, and effectiveness of the
percutaneous catheter intervention for nonrheumatic mitral
stenosis.
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